OVOL2 expression is down‐regulated in various cancers, including hepatocellular carcinoma,[13] colorectal cancer[14] and nasopharyngeal carcinoma,[16] and correlates with the clinical stage and/or histological grade in some cancers, including colorectal cancer,[14] lung adenocarcinoma,[46] osteosarcoma[47] and hepatocellular carcinoma.[13] Low OVOL2 levels are associated with poor OS in patients with hepatocellular carcinoma, colorectal cancer or nasopharyngeal carcinoma. The gene discussed is OVOL2; the disease is lung adenocarcinoma.